Treating cancer when pRb and p53 cannot be reactivated

Liang Zhu

Research output: Contribution to journalArticlepeer-review


Activation of oncoproteins and inactivation of tumor suppressors induces tumorigenesis. When these events happen upstream of pRb and p53, cancer therapies may initially succeed and then fail when pRb and p53 are activated and then re-inactivated. Therapies might succeed if they remain effective when pRb and p53 are genetically inactivated.

Original languageEnglish (US)
Article numbere1004954
JournalMolecular and Cellular Oncology
Issue number4
StatePublished - Oct 2 2015
Externally publishedYes


  • Skp2
  • cancer therapy
  • genetic inactivation
  • miR-17-92
  • p53
  • pRb

ASJC Scopus subject areas

  • Molecular Medicine
  • Cancer Research


Dive into the research topics of 'Treating cancer when pRb and p53 cannot be reactivated'. Together they form a unique fingerprint.

Cite this